Clinical Trials Browser

Approved for marketing × trilaciclib × Clear all

NCT04504513 2021-03-19

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Approved for marketing

Lung Neoplasms, Small Cell Lung Carcinoma